STAT3 in medulloblastoma: a key transcriptional regulator and potential therapeutic target.
Inhibitors
Medulloblastoma
Signal transducer and activator of transcription 3
Signaling pathway
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
04
04
2022
accepted:
08
06
2022
pubmed:
19
6
2022
medline:
2
11
2022
entrez:
18
6
2022
Statut:
ppublish
Résumé
Medulloblastoma is the most common malignant brain tumor of childhood accounting for about 60% of all pediatric embryonal tumors. Despite improvements in the overall survival rate, this tumor still lacks an efficient, reliable, and less toxic therapeutic approach. Characterization of the molecular mechanisms involved in medulloblastoma initiation and progression is a crucial step for the development of effective therapies. Signal transducer and activator of transcription 3 is a convergence point for several signaling cascades that are implicated in medulloblastoma tumorigenesis. Accumulated evidence has revealed the pivotal role of signal transducer and activator of transcription 3 in medulloblastoma pathogenesis such as proliferation, survival, angiogenesis, and immunosuppression as well as maintenance, drug resistance, and recurrence. In this review, we focus on the role of signal transducer and activator of transcription 3 in medulloblastoma tumorigenesis and discuss the recent advances of signal transducer and activator of transcription 3 inhibition as a promising developed strategy for medulloblastoma therapy.
Identifiants
pubmed: 35716286
doi: 10.1007/s11033-022-07694-6
pii: 10.1007/s11033-022-07694-6
doi:
Substances chimiques
STAT3 Transcription Factor
0
STAT3 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
10635-10652Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Khatua S et al (2018) Childhood medulloblastoma: current therapies, emerging molecular landscape and newer therapeutic insights. Curr Neuropharmacol 16(7):1045–1058
pubmed: 29189165
pmcid: 6120114
doi: 10.2174/1570159X15666171129111324
Audi ZF et al (2021) Immunosuppression in medulloblastoma: insights into cancer immunity and immunotherapy. Curr Treat Options Oncol 22(9):83
pubmed: 34328587
doi: 10.1007/s11864-021-00874-9
Ostrom QT et al (2018) CBTRUS statistical report primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol 20(suppl_4):vi1-iv86
doi: 10.1093/neuonc/noy131
Komori T (2017) The 2016 WHO classification of tumours of the central nervous System: the major points of revision. Neurol Med Chir (Tokyo) 57(7):301–311
doi: 10.2176/nmc.ra.2017-0010
Northcott PA et al (2012) Medulloblastomics: the end of the beginning. Nat Rev Cancer 12(12):818–834
pubmed: 23175120
pmcid: 3889646
doi: 10.1038/nrc3410
Kaur K et al (2016) Integrating molecular subclassification of medulloblastomas into routine clinical practice: a simplified approach. Brain Pathol 26(3):334–343
pubmed: 26222673
doi: 10.1111/bpa.12293
Northcott PA et al (2019) Medulloblastoma. Nat Rev Dis Primers 5(1):11
pubmed: 30765705
doi: 10.1038/s41572-019-0063-6
Hammoud H et al (2020) Drug repurposing in medulloblastoma: challenges and recommendations. Curr Treat Options Oncol 22(1):6
pubmed: 33245404
doi: 10.1007/s11864-020-00805-0
Dirven L et al (2020) Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. J Neurooncol 148(1):117–130
pubmed: 32367436
pmcid: 7280359
doi: 10.1007/s11060-020-03502-y
Wang Y, Levy DE (2012) Comparative evolutionary genomics of the STAT family of transcription factors. Jakstat 1(1):23–33
pubmed: 24058748
pmcid: 3670131
Chakraborty D et al (2017) Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 8(1):1130
pubmed: 29066712
pmcid: 5654983
doi: 10.1038/s41467-017-01236-6
Gu Y, Mohammad IS, Liu Z (2020) Overview of the STAT-3 signaling pathway in cancer and the development of specific inhibitors. Oncol Lett 19(4):2585–2594
pubmed: 32218808
pmcid: 7068531
Piperi C, Papavassiliou KA, Papavassiliou AG (2019) Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells 8(11):1398
pmcid: 6912524
doi: 10.3390/cells8111398
Alonzi T et al (2001) Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation in the liver. Mol Cell Biol 21(5):1621–1632
pubmed: 11238899
pmcid: 86708
doi: 10.1128/MCB.21.5.1621-1632.2001
Benito C et al (2017) STAT3 Controls the long-term survival and phenotype of repair schwann cells during nerve regeneration. J Neurosci 37(16):4255–4269
pubmed: 28320842
pmcid: 5413174
doi: 10.1523/JNEUROSCI.3481-16.2017
Huang C et al (2008) JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro. J Neuroimmunol 204(1–2):118–125
pubmed: 18710787
doi: 10.1016/j.jneuroim.2008.07.004
Wen Z, Darnell JE Jr (1997) Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res 25(11):2062–2067
pubmed: 9153303
pmcid: 146718
doi: 10.1093/nar/25.11.2062
Tkach M et al (2013) p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. Endocr Relat Cancer 20(2):197–212
pubmed: 23329648
doi: 10.1530/ERC-12-0194
Wu M et al (2019) Negative regulators of STAT3 signaling pathway in cancers. Cancer Manag Res 11:4957–4969
pubmed: 31213912
pmcid: 6549392
doi: 10.2147/CMAR.S206175
Dong Y et al (2010) Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis 31(12):2097–2104
pubmed: 20732905
doi: 10.1093/carcin/bgq167
Floss DM et al (2013) Identification of canonical tyrosine-dependent and non-canonical tyrosine-independent STAT3 activation sites in the intracellular domain of the interleukin 23 receptor. J Biol Chem 288(27):19386–19400
pubmed: 23673666
pmcid: 3707643
doi: 10.1074/jbc.M112.432153
Timofeeva OA et al (2012) Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. J Biol Chem 287(17):14192–14200
pubmed: 22378781
pmcid: 3340179
doi: 10.1074/jbc.M111.323899
Zhang X et al (2007) Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci U S A 104(10):4060–4064
pubmed: 17360477
pmcid: 1802729
doi: 10.1073/pnas.0611665104
Rozovski U et al (2018) STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget 9(72):33710–33718
pubmed: 30263097
pmcid: 6154750
doi: 10.18632/oncotarget.26110
Xu YS et al (2016) STAT3 Undergoes acetylation-dependent mitochondrial translocation to regulate pyruvate metabolism. Sci Rep 6:39517
pubmed: 28004755
pmcid: 5177931
doi: 10.1038/srep39517
Yang J et al (2010) Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci U S A 107(50):21499–21504
pubmed: 21098664
pmcid: 3003019
doi: 10.1073/pnas.1016147107
Dasgupta M et al (2015) STAT3-driven transcription depends upon the dimethylation of K49 by EZH2. Proc Natl Acad Sci U S A 112(13):3985–3990
pubmed: 25767098
pmcid: 4386339
doi: 10.1073/pnas.1503152112
Murase S (2013) Signal transducer and activator of transcription 3 (STAT3) degradation by proteasome controls a developmental switch in neurotrophin dependence. J Biol Chem 288(28):20151–20161
pubmed: 23733189
pmcid: 3711283
doi: 10.1074/jbc.M113.470583
Wei J et al (2012) The ubiquitin ligase TRAF6 negatively regulates the JAK-STAT signaling pathway by binding to STAT3 and mediating its ubiquitination. PLoS ONE 7(11):e49567
pubmed: 23185365
pmcid: 3501508
doi: 10.1371/journal.pone.0049567
Su F et al (2012) Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res 14(2):R38
pubmed: 22394684
pmcid: 3446372
doi: 10.1186/bcr3134
Li C et al (2016) SHP2, SOCS3 and PIAS3 expression patterns in medulloblastomas: relevance to STAT3 activation and resveratrol-suppressed STAT3 signaling. Nutrients. https://doi.org/10.3390/nu9010003
doi: 10.3390/nu9010003
pubmed: 28035977
pmcid: 5295047
Woetmann A et al (1999) Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci USA 96(19):10620–10625
pubmed: 10485875
pmcid: 17932
doi: 10.1073/pnas.96.19.10620
Nicholson SE et al (2000) Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 97(12):6493–6498
pubmed: 10829066
pmcid: 18633
doi: 10.1073/pnas.100135197
Chung CD et al (1997) Specific inhibition of Stat3 signal transduction by PIAS3. Science 278(5344):1803–1805
pubmed: 9388184
doi: 10.1126/science.278.5344.1803
De-Fraja C et al (1998) Members of the JAK/STAT proteins are expressed and regulated during development in the mammalian forebrain. J Neurosci Res 54(3):320–330
pubmed: 9819137
doi: 10.1002/(SICI)1097-4547(19981101)54:3<320::AID-JNR3>3.0.CO;2-R
Zhong Z, Wen Z, Darnell JE Jr (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264(5155):95–98
pubmed: 8140422
doi: 10.1126/science.8140422
Dziennis S, Alkayed NJ (2008) Role of signal transducer and activator of transcription 3 in neuronal survival and regeneration. Rev Neurosci 19(4–5):341–361
pubmed: 19145989
pmcid: 2681485
Takeda K et al (1997) Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 94(8):3801–3804
pubmed: 9108058
pmcid: 20521
doi: 10.1073/pnas.94.8.3801
Foshay KM, Gallicano GI (2008) Regulation of Sox2 by STAT3 initiates commitment to the neural precursor cell fate. Stem Cells Dev 17(2):269–278
pubmed: 18447642
doi: 10.1089/scd.2007.0098
Kanski R et al (2014) A star is born: new insights into the mechanism of astrogenesis. Cell Mol Life Sci 71(3):433–447
pubmed: 23907612
doi: 10.1007/s00018-013-1435-9
Ma X et al (2017) Stat3 controls maturation and terminal differentiation in mouse hippocampal neurons. J Mol Neurosci 61(1):88–95
pubmed: 27785757
doi: 10.1007/s12031-016-0820-x
Nicolas CS et al (2012) The Jak/STAT pathway is involved in synaptic plasticity. Neuron 73(2):374–390
pubmed: 22284190
pmcid: 3268861
doi: 10.1016/j.neuron.2011.11.024
McGregor G, Irving AJ, Harvey J (2017) Canonical JAK-STAT signaling is pivotal for long-term depression at adult hippocampal temporoammonic-CA1 synapses. Faseb j 31(8):3449–3466
pubmed: 28461339
doi: 10.1096/fj.201601293RR
Murata S et al (2000) Occurrence of a transcription factor, signal transducer and activators of transcription 3 (Stat3), in the postsynaptic density of the rat brain. Brain Res Mol Brain Res 78(1–2):80–90
pubmed: 10891587
doi: 10.1016/S0169-328X(00)00077-2
Sahin GS et al (2020) Leptin stimulates synaptogenesis in hippocampal neurons via KLF4 and SOCS3 inhibition of STAT3 signaling. Mol Cell Neurosci 106:103500
pubmed: 32438059
pmcid: 8601107
doi: 10.1016/j.mcn.2020.103500
Wan HL et al (2021) STAT3 ameliorates cognitive deficits via regulation of NMDAR expression in an Alzheimer’s disease animal model. Theranostics 11(11):5511–5524
pubmed: 33859760
pmcid: 8039956
doi: 10.7150/thno.56541
Jung JE et al (2009) Regulation of Mn-superoxide dismutase activity and neuroprotection by STAT3 in mice after cerebral ischemia. J Neurosci 29(21):7003–7014
pubmed: 19474327
pmcid: 2712132
doi: 10.1523/JNEUROSCI.1110-09.2009
Dziennis S et al (2007) Role of signal transducer and activator of transcription-3 in estradiol-mediated neuroprotection. J Neurosci 27(27):7268–7274
pubmed: 17611279
pmcid: 2570353
doi: 10.1523/JNEUROSCI.1558-07.2007
Murase S et al (2012) Loss of signal transducer and activator of transcription 3 (STAT3) signaling during elevated activity causes vulnerability in hippocampal neurons. J Neurosci 32(44):15511–15520
pubmed: 23115188
pmcid: 3504487
doi: 10.1523/JNEUROSCI.2940-12.2012
Wan J et al (2010) Tyk2/STAT3 signaling mediates beta-amyloid-induced neuronal cell death: implications in Alzheimer’s disease. J neurosci 30(20):6873–6881
pubmed: 20484629
pmcid: 6632652
doi: 10.1523/JNEUROSCI.0519-10.2010
Bian Z et al (2021) Noncoding RNAs involved in the STAT3 pathway in glioma. Cancer Cell Int 21(1):445
pubmed: 34425834
pmcid: 8381529
doi: 10.1186/s12935-021-02144-y
Yang F et al (2010) Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 8(1):35–45
pubmed: 20053726
pmcid: 2808420
doi: 10.1158/1541-7786.MCR-09-0220
Bhoopathi P et al (2011) SPARC stimulates neuronal differentiation of medulloblastoma cells via the Notch1/STAT3 pathway. Cancer Res 71(14):4908–4919
pubmed: 21613407
pmcid: 3138830
doi: 10.1158/0008-5472.CAN-10-3395
Pan L et al (2021) STAT3 inhibitor in combination with irradiation significantly inhibits cell viability, cell migration, invasion and tumorsphere growth of human medulloblastoma cells. Cancer Biol Ther 22(7–9):430–439
pubmed: 34254873
pmcid: 8489919
doi: 10.1080/15384047.2021.1951573
Ball S et al (2011) The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS ONE 6(4):e18820
pubmed: 21526200
pmcid: 3079737
doi: 10.1371/journal.pone.0018820
Chen X et al (2018) Blocking interleukin-6 signaling inhibits cell viability/proliferation, glycolysis, and colony forming activity of human medulloblastoma cells. Int J Oncol 52(2):571–578
pubmed: 29207075
Kotipatruni RR et al (2012) Apoptosis induced by knockdown of uPAR and MMP-9 is mediated by inactivation of EGFR/STAT3 signaling in medulloblastoma. PLoS ONE 7(9):e44798
pubmed: 22984561
pmcid: 3440337
doi: 10.1371/journal.pone.0044798
White CL et al (2019) A Sexually Dimorphic Role for STAT3 in Sonic Hedgehog medulloblastoma. Cancers 11(11):1702
pmcid: 6895805
doi: 10.3390/cancers11111702
Gao P et al (2017) The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis. Oncotarget 8(40):69139–69161
pubmed: 28978186
pmcid: 5620326
doi: 10.18632/oncotarget.19932
Niu G et al (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13):2000–2008
pubmed: 11960372
doi: 10.1038/sj.onc.1205260
Craveiro RB et al (2017) The anti-neoplastic activity of vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition. Oncotarget 8(29):46915–46927
pubmed: 28159923
pmcid: 5564532
doi: 10.18632/oncotarget.14911
Wang T et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10(1):48–54
pubmed: 14702634
doi: 10.1038/nm976
Abad C et al (2014) Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma. J Leukoc Biol 95(2):357–367
pubmed: 24068730
pmcid: 3896661
doi: 10.1189/jlb.1012531
Kumar V et al (2016) CD45 Phosphatase Inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity 44(2):303–315
pubmed: 26885857
pmcid: 4759655
doi: 10.1016/j.immuni.2016.01.014
Purvis IJ et al (2020) B7H3 in medulloblastoma-derived exosomes A novel tumorigenic role. Int J Mol Sci. https://doi.org/10.3390/ijms21197050
doi: 10.3390/ijms21197050
pubmed: 32992699
pmcid: 7583814
Molina-Peña R, Tudon-Martinez JC, Aquines-Gutiérrez O (2020) A mathematical model of average dynamics in a stem cell hierarchy suggests the combinatorial targeting of cancer stem cells and progenitor cells as a potential strategy against tumor growth. Cancers (Basel). https://doi.org/10.3390/cancers12092590
doi: 10.3390/cancers12092590
Bahmad HF, Poppiti RJ (2020) Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets. J Clin Pathol 73(5):243–249
pubmed: 32034059
doi: 10.1136/jclinpath-2019-206246
Liu H et al (2020) Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion. Neuro Oncol 22(5):625–638
pubmed: 31729527
doi: 10.1093/neuonc/noz214
Nazio F et al (2021) Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling. Acta Neuropathol 142(3):537–564
pubmed: 34302498
pmcid: 8357694
doi: 10.1007/s00401-021-02347-7
Garg N et al (2017) CD133 (+) brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence. Oncogene 36(5):606–617
pubmed: 27775079
doi: 10.1038/onc.2016.235
Chang CJ et al (2012) Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells. Childs Nerv Syst 28(3):363–373
pubmed: 22249380
doi: 10.1007/s00381-011-1672-x
Sreenivasan L et al (2020) Autocrine IL-6/STAT3 signaling aids development of acquired drug resistance in Group 3 medulloblastoma. Cell Death Dis 11(12):1035
pubmed: 33279931
pmcid: 7719195
doi: 10.1038/s41419-020-03241-y
Craveiro RB et al (2014) In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy. Oncotarget 5(16):7149–7161
pubmed: 25216529
pmcid: 4196191
doi: 10.18632/oncotarget.2240
Liu L et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66(24):11851–11858
pubmed: 17178882
doi: 10.1158/0008-5472.CAN-06-1377
Yang F et al (2008) Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 7(11):3519–3526
pubmed: 19001435
pmcid: 2592687
doi: 10.1158/1535-7163.MCT-08-0138
Brave SR et al (2011) Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. Int J Oncol 39(1):271–278
pubmed: 21537841
Ehrhardt M et al (2018) The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma. J Cell Mol Med 22(4):2153–2161
pubmed: 29377550
pmcid: 5867109
doi: 10.1111/jcmm.13489
Mendel DB et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1):327–337
pubmed: 12538485
Ray S et al (2018) Suppression of STAT3 NH(2) -terminal domain chemosensitizes medulloblastoma cells by activation of protein inhibitor of activated STAT3 via de-repression by microRNA-21. Mol Carcinog 57(4):536–548
pubmed: 29280516
pmcid: 6132241
doi: 10.1002/mc.22778
Schust J et al (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13(11):1235–1242
pubmed: 17114005
doi: 10.1016/j.chembiol.2006.09.018
Chen X et al (2021) LLL12B, a small molecule STAT3 inhibitor, induces growth arrest, apoptosis, and enhances cisplatin-mediated cytotoxicity in medulloblastoma cells. Sci Rep 11(1):6517
pubmed: 33753770
pmcid: 7985203
doi: 10.1038/s41598-021-85888-x
Xiao H et al (2015) A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells. J Biol Chem 290(6):3418–3429
pubmed: 25313399
doi: 10.1074/jbc.M114.616748
Sreenivasan L et al (2022) Targeting the gp130/STAT3 Axis Attenuates tumor microenvironment mediated chemoresistance in group 3 medulloblastoma cells. Cells 11(3):381
pubmed: 35159191
pmcid: 8834329
doi: 10.3390/cells11030381
Jiao Y et al (2015) Resveratrol inhibits the invasion of glioblastoma-initiating cells via down-regulation of the PI3K/Akt/NF-κB signaling pathway. Nutrients 7(6):4383–4402
pubmed: 26043036
pmcid: 4488790
doi: 10.3390/nu7064383
Mokni M et al (2007) Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem Res 32(6):981–987
pubmed: 17401679
doi: 10.1007/s11064-006-9255-z
Yu LJ et al (2008) Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells. Neoplasia 10(7):736–744
pubmed: 18592012
pmcid: 2435009
doi: 10.1593/neo.08304
Wang Q et al (2003) Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Neurosci Lett 351(2):83–86
pubmed: 14583387
doi: 10.1016/j.neulet.2003.07.002
Lu K-H et al (2009) Evaluation of radiotherapy effect in resveratrol-treated medulloblastoma cancer stem-like cells. Childs Nerv Syst 25(5):543–550
pubmed: 19225784
doi: 10.1007/s00381-009-0826-6
Lee SJ et al (2011) Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer 11(1):144
pubmed: 21501498
pmcid: 3090367
doi: 10.1186/1471-2407-11-144
Lim KJ et al (2011) A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther 11(5):464–473
pubmed: 21193839
pmcid: 3087900
doi: 10.4161/cbt.11.5.14410
Elamin MH et al (2010) Curcumin inhibits the sonic hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol Carcinog 49(3):302–314
pubmed: 20025076
doi: 10.1002/mc.20604
He M et al (2014) Curcumin suppresses cell proliferation through inhibition of the Wnt/β-catenin signaling pathway in medulloblastoma. Oncol Rep 32(1):173–180
pubmed: 24858998
doi: 10.3892/or.2014.3206
Xu XT et al (2017) Celecoxib enhances the radiosensitivity of HCT116 cells in a COX-2 independent manner by up-regulating BCCIP. Am J Transl Res 9(3):1088–1100
pubmed: 28386336
pmcid: 5376001
Liu DB et al (2012) Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin 33(5):682–690
pubmed: 22504904
pmcid: 4010355
doi: 10.1038/aps.2012.18
Yang MY et al (2014) Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells. Int J Mol Sci 15(6):11013–11029
pubmed: 24945311
pmcid: 4100195
doi: 10.3390/ijms150611013
el Dakir H et al (2018) The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer. Oncotarget 9(79):34889–34910
pmcid: 6201850
doi: 10.18632/oncotarget.26175
Zhou W et al (2016) The antipsychotic drug pimozide inhibits cell growth in prostate cancer through suppression of STAT3 activation. Int J Oncol 48(1):322–328
pubmed: 26549437
doi: 10.3892/ijo.2015.3229
Ranjan A, Kaushik I, Srivastava SK (2020) Pimozide suppresses the growth of brain tumors by targeting STAT3-mediated autophagy. Cells. https://doi.org/10.3390/cells9092141
doi: 10.3390/cells9092141
pubmed: 32971907
pmcid: 7563195
Rahaman SO et al (2002) Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21(55):8404–8413
pubmed: 12466961
doi: 10.1038/sj.onc.1206047
Han ES et al (2018) Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer. Oncotarget 9(36):24304–24319
pubmed: 29849942
pmcid: 5966246
doi: 10.18632/oncotarget.24368
Ando S et al (2016) Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Oncotarget 7(47):76793–76805
pubmed: 27732937
pmcid: 5363550
doi: 10.18632/oncotarget.12529
Haile WB et al (2016) The janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol Dis 92(Pt B):137–143
pubmed: 26851503
pmcid: 4907871
doi: 10.1016/j.nbd.2016.02.007
Wei J et al (2019) Targeting upstream kinases of STAT3 in human MEDULLOBLASTOMA cells. Curr Cancer Drug Targets 19(7):571–582
pubmed: 30332965
pmcid: 6533162
doi: 10.2174/1568009618666181016165604
Blaskovich MA et al (2003) Discovery of JSI-124 (cucurbitacin I), a selective janus KINASE/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63(6):1270–1279
pubmed: 12649187
Lo HW et al (2008) Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 14(19):6042–6054
pubmed: 18829483
pmcid: 2707832
doi: 10.1158/1078-0432.CCR-07-4923
Garcia R et al (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20(20):2499–2513
pubmed: 11420660
doi: 10.1038/sj.onc.1204349
Siddiquee K et al (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 104(18):7391–7396
pubmed: 17463090
pmcid: 1863497
doi: 10.1073/pnas.0609757104
Ferrajoli A et al (2007) WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 67(23):11291–11299
pubmed: 18056455
doi: 10.1158/0008-5472.CAN-07-0593
Groot J et al (2022) A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. https://doi.org/10.2217/cns-2022-0005
doi: 10.2217/cns-2022-0005
pubmed: 35575067
pmcid: 9134932
Mandal T et al (2014) Reduced phosphorylation of Stat3 at Ser-727 mediated by casein kinase 2—protein phosphatase 2A enhances Stat3 Tyr-705 induced tumorigenic potential of glioma cells. Cell Signal 26(8):1725–1734
pubmed: 24726840
doi: 10.1016/j.cellsig.2014.04.003
D’Arcy BM et al (2019) The antitumor drug LB-100 Is a catalytic inhibitor of protein phosphatase 2A (PPP2CA) and 5 (PPP5C) coordinating with the active-site catalytic metals in PPP5C. Mol Cancer Ther 18(3):556–566
pubmed: 30679389
pmcid: 6397705
doi: 10.1158/1535-7163.MCT-17-1143
Ho WS et al (2016) PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells. Oncotarget 7(11):12447–12463
pubmed: 26799670
pmcid: 4914297
doi: 10.18632/oncotarget.6970
Jagadeesan S, Hakkim A (2018) RNAi Screening: automated high-throughput liquid RNAI screening in caenorhabditis elegans. Curr Protoc Mol Biol 124(1):e65
pubmed: 30204302
pmcid: 6168420
doi: 10.1002/cpmb.65
Di Silvio D et al (2019) Self-assembly of poly(allylamine)/siRNA nanoparticles, their intracellular fate and siRNA delivery. J Colloid Interface Sci 557:757–766
pubmed: 31569055
doi: 10.1016/j.jcis.2019.09.082
Kulakova A et al (2020) Albumin-neprilysin fusion protein: understanding stability using small angle X-ray scattering and molecular dynamic simulations. Sci Rep 10(1):10089
pubmed: 32572086
pmcid: 7308280
doi: 10.1038/s41598-020-67002-9
Marsh JA et al (2013) Protein complexes are under evolutionary selection to assemble via ordered pathways. Cell 153(2):461–470
pubmed: 23582331
pmcid: 4009401
doi: 10.1016/j.cell.2013.02.044
Rafei M et al (2011) A MCP1 fusokine with CCR2-specific tumoricidal activity. Mol Cancer 10:121
pubmed: 21943176
pmcid: 3189909
doi: 10.1186/1476-4598-10-121
Chlenski A et al (2006) SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer 118(2):310–316
pubmed: 16052522
doi: 10.1002/ijc.21357
Chetty C et al (2012) SPARC expression induces cell cycle arrest via STAT3 signaling pathway in medulloblastoma cells. Biochem Biophys Res Commun 417(2):874–879
pubmed: 22206672
doi: 10.1016/j.bbrc.2011.12.065